A KRAS<sup>G12V</sup>-targeted bispecific T cell engager promotes immunity against colorectal solid tumor
Huynh N., Nguyen TT., Bui NT., Nguyen HN., Nguyen CT.
Laboratory Study, published in Mol Ther Oncol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Mol Ther Oncol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41438133
- PMCID
- PMC12721267
- DOI
- 10.1016/j.omton.2025.201098
- Citations
- 1
Abstract (original English)
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations have been detected at high rates in various tumor types, making them one of the most commonly mutated oncogenes. Limited relevant binding pockets have rendered these mutants undruggable for many decades, particularly the KRAS G12V mutant. Recent advances in T cell receptor (TCR) profiling have provided a new strategy for overcoming this limitation by recognizing neoantigens presented by human lymphocyte antigen (HLA) and inducing T cell-mediated killing responses. Using the previously identified KRAS G12V -targeting TCR, we engineered bispecific T cell engager receptors (TCERs) with high efficiency and specificity for the KRAS G12V /HLA-A∗11:01 tetramer. Specifically, TCER01 and TCER02 effectively induced T cell-mediated tumor killing in 2D and 3D in vitro models of solid colorectal tumor cells. The binding and functional assessment of TCER01 and TCER02 exhibited high specificity for the KRAS G12V 9-mer peptide while showing minimal cross-reactivity to other homologs. TCER01 activity is unique for HLA-A∗11:01, which is distinct from other KRAS G12V -presenting HLAs. Our study proposes a potential new therapeutic option for KRAS G12V colorectal cancer and extends our knowledge for developing TCER-based tumor immunotherapies.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.